Opinion|Videos|September 30, 2024

Factors to Consider When Switching Therapies

The discussion covers when to consider transitioning to a new therapeutic option in CLL and the factors that influence the decision between dose modification and switching therapies.

Video content above is prompted by the following:

  • When is transitioning to a new therapeutic option considered, and what factors influence the decision between dose modification and switching therapies in chronic lymphocytic leukemia treatment?

Related to this article

Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.